Update from the Board of Directors
(Oslo, Norway, 28 April 2016) Bionor Pharma ASA (OSE:BIONOR) announces that the Board of Directors is currently reviewing the company’s strategy and financing plans and will announce any possible changes in due course in a stock exchange announcement.
The company maintains its focus on HIV immunotherapy and overall strategy to advance Vacc-4x in combination with other medicines in order to contribute to a possible functional HIV cure. The timing and details in the clinical development program is under consideration in light of the company’s cash position and market capitalization.
Per S. Thoresen, Chairman of the Board of Bionor said: “It is of course not a perfect situation that the CEO and three board members leave the company in a short period of time, but a change in strategy will naturally lead to some changes in a company’s leadership. We have a strong asset in Vacc-4x, and as Board and company, we look forward to advancing our functional HIV cure strategy to the future benefit of the HIV positive individuals, their caregivers and shareholders, and will announce any further adjustments in due course.”
Per S. Thoresen, Chairman of the Board of Directors, +47 906 14 620
Bionor Pharma is a Norwegian biopharmaceutical company focused on advancing its proprietary therapeutic vaccine Vacc-4x in combination with other medicines toward a functional HIV cure. The company believes it has first mover potential based on clinical results to date and early adoption of now recognized clinical strategy. In December 2015, Bionor announced that the HIV ’Shock & Kill’ trial REDUC with Vacc-4x and romidepsin successfully met its primary endpoint by reducing latent HIV reservoir and further demonstrated control of viral load. Bionor currently retains full ownership rights to Vacc-4x, i.e., the upside potential from partnering or licensing remains with the company. Bionor is based in Oslo, Norway, and also has offices in Copenhagen, Denmark and New York, USA. Bionor is listed on Oslo Børs (OSE:BIONOR). More information about Bionor is available at www.bionorpharma.com.